INVESTIGATION OF RELATIONSHIP BETWEEN rs1800796 VARIANTS OF INTERLEUKINE-6 GENE AND CORONARY ARTERY DISEASE

Yıl 2019, Cilt: 8 Sayı: 1, 98 - 105, 01.01.2019

Halil İbrahim Güler

Öz

The most important characteristic of coronary artery disease, which is one of the most common and most important health problems today, is that it can lead to life-threatening myocardial infarction in advanced stages. It is more important to take protective preventions by knowing the risk factors that cause the disease rather than the treatment of this disease. This study was performed on coronary artery disease (CAD) to determine the frequency of the interleukin-6 gene (IL-6) 572G/C polymorphism and to examine the role of this polymorphism in CAD development. Genomic DNA obtained from 185 persons (103 CAD patients, 82 controls) was used in the study. IL-6 572 G/C polymorphism genotypes were determined using PCR, RFLP and electrophoresis. The results were statistically analyzed. The frequencies of 572 G/C genotypes, in controls GG 83%, GC 17%, CC 0% and in CAD patients GG 72% , GC 28% and CC 0% were found. There was no significant difference between the control group and the patient groups in genotype frequencies. It was determined that GG genotype frequency increases significantly in patients according to control group. Based on the results of our study, we may suggest that there is no association between CAD and IL-6 572G / C polymorphism.

Anahtar Kelimeler

Coronary Artery Disease, CAD, IL-6 polymorphism, rs1800796

Kaynakça

• [1] Çelik A, Özçetin M, Ateş Ö, Altunkaş F, Karaman K, Akar İ, İnce İ, Yalçın M, Karayakalı M, Ceyhan K, Koç F. Analyses of C-Reactive Protein, Endothelial Nitric Oxide Synthase and Interleukin-6 Gene Polymorphisms in Adolescents with a Family History of Premature Coronary Artery Disease. A Pilot Study. Balkan Med J. 2015; 32(4):397-402.
• [2] Özer K, Büyükateş M, Dursun A, Aktunç E, Turan SA, Doğan SM, Aydın M. Comparison Of Gene Polymorphisms In Severe Atherosclerotic Patients In Different Age Groups. Gazi Medical Journal 2009; 20 (3), 124-127
• [3] Karaman E, Kucuk MU, Bayramoglu A, Gocmen SU, Ercan S, Güler Hİ, et al. Investigation of relationship between IL-6 gene variants and hypertension in Turkish population. Cytotechnology 2015; 67: 947-954.
• [4] Chen H, Ding S, Liu X, Liu J, Wu J, Wu X. Association of Interleukin-6 Genetic Polymorphisms and Environment Factors Interactions with Coronary Artery Disease in a Chinese Han Population, Clin Exp Hypertens 2018; 11:1-4.
• [5] Hongmei Y, Yongping J, Jiyuan L. Interleukin-6 polymorphisms and risk of coronary artery diseases in a Chinese population: A case-control study. Pak J Med Sci 2016;. 32(4):880-5.
• [6] Hou H, Wang C, Sun F, Zhao L, Dun A, Sun Z. Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis. Inflamm. Res. 2015; 64:707–720.
• [7] Cattaruzza M, Guzik TJ, Słodowski W, Pelvan A, Becker J, Halle M, Buchwald AB, Channon KM Hecker M. Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res. 2004; 95(8): 841-7.
• [8] Harada K, Amano T, Uetani T, Yoshida T, KatoB, Kato M, Marui N, Kumagai S, Ando H, Ishii H, Matsubara T, Murohara T. Association of inflammatory markers with the morphology and extent of coronary plaque as evaluated by 64-slice multidetector computed tomography in patients with stable coronary artery disease. Int J Cardiovasc Imaging 2013; 29(5): 1149-1158.
• [9] Niu W, Liu Y, Qi Y, Wu Z, Zhu D, Jin W. Association of interleukin-6 circulating levels with coronary artery disease: A meta-analysis implementing mendelian randomization approach, International Journal of Cardiology 2012; 157 (2): 243–252.
• [10] Yang Y, Zhang F, Skrip L, Lei H, Wang Y, Hu D, Ding R. IL-6 gene polymorphisms and CAD risk: a meta-analysis, Mol Biol Rep. 2013; 40(3): 2589–2598.
• [11] Uydu HA, Bostan M, Yilmaz A, Demir A, Atak M, Satiroglu Ö, Temiz A, Cicek Y, Erdogan T, Cetin M, Canga A. Comparison of inflammatory biomarkers for detection of coronary stenosis in patients with stable coronary artery disease, European Review for Medical and Pharmacological Sciences 2013; 17(1): 112-118.
• [12] Pignone M, Alberts MJ, Colwell JA, Cushman M, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J. Am. Coll. Cardiol. 2010; 55: 2878-2886.
• [13] Jabir NR, Firoz CK, Kamal MA, Damanhouri GA, Alama MN, Alzahrani AS, Almehdar HA, Tabrez S. Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients. J Clin Lab Anal. 2017; 31(5): Epub 2016 Nov 9.
• [14] Sun GQ., Wu GD, Meng Y, Du B, Li YB. IL-6 gene promoter polymorphisms and risk of coronary artery disease in a Chinese population, Genet. Mol. Res. 2014; 13(3): 7718-7724
• [15] Altekin E, Onvural B. Usefulness Of C-Reactive Protein In Cardiovascular Disease As A Risk Factor. T Klin J Med Sci. 2004; 24: 57-61.[16] de Maat MP, Kluft C. The association between inflammation markers, coronary artery disease and smoking, Vascular Pharmacology 2002; 39: 137– 139
• [17] Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two Promoter Polymorphisms Regulating Interleukin-6 Gene Expression Are Associated with Circulating Levels of C-Reactive Protein and Markers of Bone Resorption in Postmenopausal Women, J Clin Endocrinol Metab. 2003; 88(1): 255–259.
• [18] Mahalle N, Garg M, Kulkarni M, Naik S. Association of inflammatory cytokines with traditional and nontraditional cardiovascular risk factors in Indians with known coronary arterydisease. Ann Med Health Sci Res. 2014; 4:706–12.
• [19] Ghazouani L, Abboud N, Ben Hadj Khalifa S, Added F, Ben Khalfallah A, Nsiri B, Mediouni M, Mahjoub T. 174 G/C interleukin-6 gene polymorphism in Tunisian patients with coronary artery disease, Ann Saudi Med. 2011; 31: 40–4.
• [20] Yin YW, Sun QQ, Zhang BB, Hu AM, Liu HL, Wang Q, Zeng YH, Xu RJ, Zhang ZD, Zhang ZG. Association between the Interleukin-6 Gene −572 C/G Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Meta-Analysis of 11,681 Subjects, Annals of Human Genetics 2013; 77(2): 106–114.
• [21] Coker A, Arman A, Soylu O, Tezel T, Yildirim A. Lack of association between IL-1 and IL-6 gene polymorphisms and myocardial infarction in Turkish population, International Journal of Immunogenetics 2010; 38: 201–208.
• [22] Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215
• [23] Kelberman D, Hawe E, Luong LA, Mohamed-Ali V, Lundman P, Tornvall P, et al. Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromb Haemost 2004; 92(5):1122–1128
• [24] Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men, Eur Heart J. 2001; 22(24): 2243-52.
• [25] Georges JL, Loukaci V., Poirier O., Evans A., Luc G., Arveiler D., Ruidavets J.B., Cambien F. and Tiret L., 2001 Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Te´moin de l’Infarctus du Myocarde, J Mol Med Berl., 79(5-6), 300–305
• [26] Fragoso J.M, Delgadillo H, Jua´rez-Cedillo T, Rodrı´guez-Pe´rez JM, Vallejo M, Pe´rez-Me´ndez O, Alvarez-León E, Peña-Duque MA, Martínez-Ríos MA, Vargas-Alarcón G. The interleukin 6–572 G/C (rs1800796) polymorphism is associated with the risk of developing acute coronary syndrome, Genet Test Mol Biomarkersm 2010; 14(6): 759–763.
• [27] Jia X, Tian Y, Wang Y, Deng X, Dong Z, Scafa N. Association between the interleukin-6 gene -572G/C and -597G/A polymorphisms and coronary heart disease in the Han Chinese, Med Sci Monit. 2010; 16(3): 103–108.
• [28] Wei YS, Lan Y, Liu YG, Tang RG, Lan JS. Relationship between interleukin-6 gene polymorphism and coronary heart disease and its effect on plasma lipid levels. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2006; 18(4): 233–236.
• [29] Jang Y, Kim OY, Hyun YJ, et al. Interleukin- 6- 572C>G polymorphism- association with inflammatory variables in Korean men with coronary artery disease. J Lab Clin Med. 2008; 151: 154–161.
• [30] Li YY, Zhou CW, Xu J, Qian Y, Wang XM. Interleukin-6 C-572G gene polymorphism and coronary artery disease in Asian: a meta-analysis of 2511 subjects, Int J Clin Exp Med 2015; 8(6): 8995-9003.
• [31] Li L, Li E, Zhang LH, Jian LG, Liu HP, Wang T. IL-6-174G/C and IL-6-572C/G polymorphisms are associated with increased risk of coronary artery disease, Genetics and Molecular Research 2014; 14 (3): 8451-8457.
• [32] Wang K, Dong PS, Zhang H, Li ZJ, Yang XM Liu H. Role of interleukin-6 gene polymorphisms in the risk of coronary artery disease, Genetics and Molecular Research 2015; 14 (2): 3177-3183.
• [33] Fu HX, Li GS, Li Y, Xu JL, Zhang JY. Interleukin-6-597G/A and-572C/G polymorphisms and risk of coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34(6): 519–522.
• [[16] de Maat MP, Kluft C. The association between inflammation markers, coronary artery disease and smoking, Vascular Pharmacology 2002; 39: 137– 139